StockNews.AI

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

StockNews.AI • 1 minute

GNCACLDX
High Materiality8/10

Information

CEO Shaun Bagai to Discuss RenovoRx's Commercial and Clinical Program Progress CEO Shaun Bagai to Di...

Original source

AI Summary

CEO Shaun Bagai to update on RenovoRx’s commercial progress at AlphaNorth Capital Event. Growing demand for RenovoCath® among top cancer centers supports RNXT's market potential. Ongoing Phase III clinical trial for intra-arterial gemcitabine will be discussed. Support for investigator-initiated trials may expand TAMP™ therapy's clinical utility. Commercialization efforts for RenovoCath are actively advancing from initial orders.

Sentiment Rationale

Increased adoption and clinical progress suggest positive growth potential, similar to trends seen with other biotech stocks after successful trials. Notably, companies often experience stock price increases when FDA-cleared products demonstrate strong market demand and clinical validation.

Trading Thesis

Immediate impact expected from the upcoming investor event; significant announcements can influence stock prices quickly, as seen in past biotechnology gatherings where clinical data or adoption rates were shared.

Market-Moving

  • CEO Shaun Bagai to update on RenovoRx’s commercial progress at AlphaNorth Capital Event.
  • Growing demand for RenovoCath® among top cancer centers supports RNXT's market potential.
  • Ongoing Phase III clinical trial for intra-arterial gemcitabine will be discussed.

Key Facts

  • CEO Shaun Bagai to update on RenovoRx’s commercial progress at AlphaNorth Capital Event.
  • Growing demand for RenovoCath® among top cancer centers supports RNXT's market potential.
  • Ongoing Phase III clinical trial for intra-arterial gemcitabine will be discussed.
  • Support for investigator-initiated trials may expand TAMP™ therapy's clinical utility.
  • Commercialization efforts for RenovoCath are actively advancing from initial orders.

Companies Mentioned

  • GNCA (GNCA)
  • CLDX (CLDX)

Corporate Developments

The article outlines critical developments that signal growth potential and clinical advancements for RNXT, directly influencing investor sentiment and interest.

RenovoRx to Present at AlphaNorth Capital Event: Insights on Commercial and Clinical Advances

MOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (Nasdaq: RNXT), a pioneering life sciences company focused on targeted oncology therapies, has announced that CEO Shaun Bagai will be participating in the upcoming AlphaNorth Capital Event. The conference is set to take place from January 16-18, 2026, at the Grand Hyatt Baha Mar in Nassau, Bahamas. Mr. Bagai will provide updates on RenovoRx’s commercial progress and clinical initiatives, showcasing the increasing adoption of the company’s innovative drug-delivery device, RenovoCath®.

Highlighting RenovoCath®: A Breakthrough in Drug Delivery

During the event, Mr. Bagai will delve into the surge in demand for RenovoCath®, which has been increasingly embraced as a standalone targeted drug-delivery device. This growing adoption among both new and returning customers, including prestigious cancer centers, underscores the rising need for localized, targeted treatments.

RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform drives this demand, allowing for more effective administration of therapeutic agents directly to tumor sites.

Phase III TIGeR-PaC Clinical Trial Update

In addition to discussing commercial advancements, Mr. Bagai will provide insights into RenovoRx’s ongoing Phase III clinical trial, known as TIGeR-PaC. This study evaluates the potential of intra-arterial gemcitabine (IAG), delivered via RenovoCath, in treating patients with locally advanced pancreatic cancer (LAPC).

The company is also developing a post-marketing observational registry aimed at gathering real-world safety and survival data across various solid tumors. Mr. Bagai will emphasize RenovoRx’s commitment to supporting capital-efficient, investigator-initiated trials to further enhance the clinical utility of the TAMP™ therapy platform.

Event Details and Investor Meetings

Investors and stakeholders interested in a one-on-one meeting with Mr. Bagai during the AlphaNorth Capital Event are encouraged to contact KCSA Strategic Communications at RenovoRx@KCSA.com.

  • Date: January 16-18, 2026
  • Location: Grand Hyatt Baha Mar, Nassau, Bahamas

About RenovoRx and RenovoCath®

RenovoRx, Inc. (NASDAQ: RNXT) is dedicated to addressing high unmet medical needs by developing innovative targeted oncology therapies. At the core of its offerings is RenovoCath®, an FDA-cleared device designed for the isolation of blood flow and delivery of fluids, including both diagnostic and therapeutic agents.

The Trans-Arterial Micro-Perfusion (TAMP™) platform offers a novel approach to delivering treatments directly to tumors while potentially reducing systemic toxicity associated with traditional intravenous methods. This strategic focus enables RenovoRx to enhance safety, tolerance, and treatment efficacy for cancer patients.

Commercialization Efforts and Future Outlook

RenovoRx is actively commercializing TAMP technology alongside the RenovoCath® device. In December 2024, the company marked a significant milestone by receiving its first commercial purchase orders for RenovoCath devices, with several customers already placing repeat orders. This momentum is particularly notable as new medical institutions also commence orders for RenovoCath®.

To keep pace with rising demand, RenovoRx is poised to explore additional revenue-generating opportunities, either independently or in collaboration with commercial partners.

Forward-Looking Statements

This announcement contains forward-looking statements concerning RenovoRx, including statements about future clinical trials, product candidates, and commercialization strategies. These statements reflect the company's current expectations and are subject to risks and uncertainties that could cause actual results to differ.

For further details, visit www.renovorx.com and follow RenovoRx on social media platforms including Facebook, LinkedIn, and X.

Related News